Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Alessandra Baldoni et al.|The Lancet Oncology|2021Cited by 412
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup StudyIgnace Vergote, Éric Pujade-Lauraine|Journal of Clinical Oncology|2013Cited by 113
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.Andrés Poveda, Éric Pujade-Lauraine, Anne Floquet et al.|Journal of Clinical Oncology|2020Cited by 110
579P A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detectionA. Buisson, I. Ray-Coquard, Pierre Saintigny et al.|Annals of Oncology|2022Cited by 1